These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36690875)

  • 21. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of HLA-DRB1-restricted CD4⁺ T cell responses with HIV immune control.
    Ranasinghe S; Cutler S; Davis I; Lu R; Soghoian DZ; Qi Y; Sidney J; Kranias G; Flanders MD; Lindqvist M; Kuhl B; Alter G; Deeks SG; Walker BD; Gao X; Sette A; Carrington M; Streeck H
    Nat Med; 2013 Jul; 19(7):930-3. PubMed ID: 23793098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
    Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
    Front Immunol; 2022; 13():794684. PubMed ID: 35720386
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of an HLA-DPB1*0501 restricted Melan-A/MART-1 epitope recognized by CD4+ T lymphocytes: prevalence for immunotherapy in Asian populations.
    Meng Z; Wang Y; Zhang G; Ke Y; Yan Y; Wu L; Huang Q; Zeng G; Wang Y; Ying H; Jiao S
    J Immunother; 2011 Sep; 34(7):525-34. PubMed ID: 21760531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clonality of CD4
    Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
    Front Immunol; 2019; 10():1336. PubMed ID: 31275310
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.
    Martins Nascentes Melo L; Herrera-Rios D; Hinze D; Löffek S; Oezel I; Turiello R; Klein J; Leonardelli S; Westedt IV; Al-Matary Y; Egea-Rodriguez S; Brenzel A; Bau M; Sucker A; Hadaschik E; Wirsdörfer F; Hanenberg H; Uhlenbrock N; Rauh D; Poźniak J; Rambow F; Marine JC; Effern M; Glodde N; Schadendorf D; Jablonska J; Hölzel M; Helfrich I
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37028818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis.
    Scally SW; Petersen J; Law SC; Dudek NL; Nel HJ; Loh KL; Wijeyewickrema LC; Eckle SB; van Heemst J; Pike RN; McCluskey J; Toes RE; La Gruta NL; Purcell AW; Reid HH; Thomas R; Rossjohn J
    J Exp Med; 2013 Nov; 210(12):2569-82. PubMed ID: 24190431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers.
    Shklovskaya E; Pedersen B; Stewart A; Simpson JOG; Ming Z; Irvine M; Scolyer RA; Long GV; Rizos H
    Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intratumoral Immunotherapy-Update 2019.
    Hamid O; Ismail R; Puzanov I
    Oncologist; 2020 Mar; 25(3):e423-e438. PubMed ID: 32162802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.
    Robbins PF; El-Gamil M; Li YF; Zeng G; Dudley M; Rosenberg SA
    J Immunol; 2002 Nov; 169(10):6036-47. PubMed ID: 12421991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
    Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
    J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
    Berg L; Rönnelid J; Sanjeevi CB; Lampa J; Klareskog L
    Arthritis Res; 2000; 2(1):75-84. PubMed ID: 11219392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.
    Depontieu FR; Qian J; Zarling AL; McMiller TL; Salay TM; Norris A; English AM; Shabanowitz J; Engelhard VH; Hunt DF; Topalian SL
    Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12073-8. PubMed ID: 19581576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.
    Bakhru P; Zhu ML; Wang HH; Hong LK; Khan I; Mouchess M; Gulati AS; Starmer J; Hou Y; Sailer D; Lee S; Zhao F; Kirkwood JM; Moschos S; Fong L; Anderson MS; Su MA
    JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy.
    Dissanayake SK; Thompson JA; Bosch JJ; Clements VK; Chen PW; Ksander BR; Ostrand-Rosenberg S
    Cancer Res; 2004 Mar; 64(5):1867-74. PubMed ID: 14996751
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T-cell receptor-HLA-DRB1 associations suggest specific antigens in pulmonary sarcoidosis.
    Grunewald J; Kaiser Y; Ostadkarampour M; Rivera NV; Vezzi F; Lötstedt B; Olsen RA; Sylwan L; Lundin S; Käller M; Sandalova T; Ahlgren KM; Wahlström J; Achour A; Ronninger M; Eklund A
    Eur Respir J; 2016 Mar; 47(3):898-909. PubMed ID: 26585430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients.
    Kitano S; Tsuji T; Liu C; Hirschhorn-Cymerman D; Kyi C; Mu Z; Allison JP; Gnjatic S; Yuan JD; Wolchok JD
    Cancer Immunol Res; 2013 Oct; 1(4):235-44. PubMed ID: 24396833
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.
    Gunjur A; Klein O; Kee D; Cebon J
    J Immunother Cancer; 2019 Sep; 7(1):241. PubMed ID: 31488221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses.
    Brentville VA; Metheringham RL; Daniels I; Atabani S; Symonds P; Cook KW; Vankemmelbeke M; Choudhury R; Vaghela P; Gijon M; Meiners G; Krebber WJ; Melief CJM; Durrant LG
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32561639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.